quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 8, 2025

IGEL läutet neue Ära der EUC-Transformation und vertrauenswürdigen Endpunktsicherheit ein

View original at globenewswire.com
IGEL läutet neue Ära der EUC-Transformation und vertrauenswürdigen Endpunktsicherheit ein Europas führende Veranstaltung zum Thema EUC und Endpunktsicherheit versammelt Microsoft, Omnissa, HP, Lenovo, Zscaler, Palo Alto Networks und weitere Unternehmen, um die Zukunft von Zero Trust, Kontinuität und widerstandsfähigem…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The IGEL Now & Next Frankfurt event demonstrated a level of innovation and implementation that is truly outstanding in the endpoint market. With their prevention-oriented approach characterized by high ROI and comprehensive partner integration, they are setting new standards for secure and adaptable digital work environments. For all companies prioritizing zero trust, resilience and cost efficiency, IGEL is clearly pointing the way forward

    80% confidence
  • With the completion of an exceptional IGEL Now & Next week in Frankfurt, the urgency to rethink endpoint security has become clearer than ever

    80% confidence
  • The IGEL Adaptive Secure Desktop is the logical continuation of our mission: to enable secure, flexible and human-centric digital workplaces. What's special about it is the integrated intelligence - it's not just about who the user is, but also where they are, how they connect, and what the level of trust is at any given moment. In this way, we realize a true zero trust architecture and enforce policies at the endpoint

    80% confidence
  • For IGEL, prevention means much more than just adding features. It is our commitment to protecting the infrastructure that secures critical sectors like government, financial services, healthcare, manufacturing, transportation and utilities that are essential to the cyber resilience of every country

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com